Back to EZorb Newsletter Index

In this issue:

1. Share Success: Letters From Readers
2. Research News: Racial Difference Found In Poor Diabetes Outcome
3. Useful Links
4. What Are Others Saying About EZorb and Marvlix?

Letter I: From Candice W.
Received at Testimonial Submit Form Monday, July 12, 2021 at 10:34:54
(Unedited)

Hi, my name is Candy. I first started taking Ezorb Nov 2019.

I had injured my left foot while walking. When my foot started to swell, I had an x-ray that revealed a significant bone spur and arthritis in the foot.

I searched the web for what I could do for the pain in my foot and came across EZorb. I also had been diagnosed with osteoporosis.

It is now July 2021. I wish I could recall when my symptoms abated. I have had no pain in the foot for a very long time.

My repeat bone scan showed improvement in my hip osteoporosis.

I am thrilled with this product. I just placed a reorder, and now I am going to add Marvlix. Thank you.

Our newsletter reaches over 200,000 subscribers worldwide. Success stories you shared in the past have made a great impact on many people's life.

Please email your story to sharesuccess @ ezorbonline.com or simply post it to Testimonial Submit Form. Your personal information will never be revealed to the public.

A large systematic review and meta-analysis has identified racial/ethnic differences in the risk for complications and all-cause mortality among people with diabetes.

“Our findings reinforce the need for improving identification of high-risk groups, and for intensive control of cardiovascular (CV) risk factors across ethnically diverse populations, which may help delay and/or prevent a considerable proportion of future diabetic complications,” say Antonio García-Hermoso (Public University of Navarra, Pamplona, Spain) and co-authors.

The team analyzed data from 23 cohort studies involving more than 2.4 million people with diabetes, among whom there were 37,530 deaths, 5121 CV events, 90,125 cases of nephropathy, and 69,107 amputations over an average follow-up of 8.15 years.

As reported in Diabetologia, Maori people (n=56,966) had a significant 88% higher risk for mortality than White people (n=1,433,975), at estimated rates of 0.42% versus 0.15%. There were no significant differences in mortality risk among Black, Hispanic-American, or Pacific Islander versus White people, however.

These findings “are consistent with previous studies, which also reported Indigenous disparities in mortality risk among individuals with diabetes,” say García-Hermoso et al.

The researchers suggest that variables such as poor glycemic control, obesity, and socioeconomic disadvantage could partly explain the elevated mortality risk in Maori people, but note that these factors “do not explain the magnitude of the difference between Maori and other minority groups, such as Pacific Islanders,” considering their shared ancestry and similar access to care.

“The modifiable risk factors and health barriers contributing to the health disparities among Maori individuals with diabetes should, therefore, be identified and explored,” they say.

In the analysis of complications, Hispanic–American individuals (n=57,416) had a significant 34% lower risk for CV events and Black people (n=270,279) had a significant 54% higher risk for end-stage renal disease than their White counterparts. García-Hermoso and team note that other racial/ethnic groups (East and South Asian, Native American, or Pacific Islander) had a comparable risk for diabetes complications relative to White people.

These findings suggest that “screening for early kidney disease, rigorous management of risk factors and further research on the aetiology of renal disease among Black individuals with diabetes” is warranted, say the study authors.

Despite the reduced risk for CV events among Hispanic-American people, the researchers stress that “intensive control of cardiovascular risk factors is recommended as in other racial/ethnic groups,” given that “it is unknown whether a protective effect against the development of macrovascular complications is present in Hispanic-American individuals.”

Original research was published in Diabetologia 2021; doi:10.1007/s00125-021-05554-9.

EZorb - Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index